At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

Doctors have been fairly quick to jump on the biologics train: According to Spherix, 96% of dermatologists reported using ...

AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...

AbbVie is best known for its blockbuster drug Humira – used to treat rheumatoid arthritis and Crohn’s disease, among others. Humira’s sales peaked at $21.2 billion in 2022, before falling 32 ...

AbbVie Inc . (NYSE:ABBV), a leading biopharmaceutical company, has been navigating a critical transition period as it faces the loss of exclusivity (LOE) for its blockbuster drug Humira.

AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed ...